TRUPANION, INC.

TRUP
About the company

Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, and Continental Europe. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians. The company was formerly known as Vetinsurance International, Inc. and changed its name to Trupanion, Inc.

Country: United StatesPrice: $34.48Market Cap: $1.5B

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

3 / 13

NEUTRAL / FAIL

Median fair value

$9.46

-72.6% vs price

Models with upside

2 / 16

Positive margin of safety

Strongest signal

8 of 11 pass — Buffett, Marks and Asness object

Key risk

All 4 investors flag TRUP's efficiency

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNEUTRALFAILFAILFAILFAILFAILNEUTRALFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety-264.3%-498.6%N/AN/AN/A+16.8%-343.8%N/AN/A+44.6%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-13

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage73% pass✓ 10✗ 3▾

    8 of 11 pass — Buffett, Marks and Asness object

    Debt/Equity & Interest CoverageD/E: 0.26, IC: 2.9x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.26
    ✓Lynch< 0.33
    Cash - Long-term Debt$75.9M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change15.81% -> 11.12%
    ✓PiotroskiDecreased YoY
    Total Debt / Shareholders' Equity0.26
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.26
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=2.9x, D/EBITDA=2.4x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.26
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.2617; #1886/4210 (top 44.8%)
    ✗AsnessTop 30% of eligible cross-section
    Current Assets / Current Liabilities1.74x
    ✓SchlossCurrent ratio >= 1.50x (app cutoff)

Where It Falls Short

  • Efficiency0% pass✗ 5▾

    All 4 investors flag TRUP's efficiency

    Revenue / Total Assets Change YoY1.59x -> 1.57x
    ✗PiotroskiImproved YoY
    Return on Invested Capital4.4%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-7.4%; FY2024: ROIC=-1.7%; FY2025: ROIC=2.3%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC2.3% (RR=100% x ROIC=2.3%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest 2.3%)
    ✗SleepROIC > 12% in a majority of years
  • Verdicts0% pass✗ 13▾

    Split decision: 13 FAIL · 3 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (1/7)✗BuffettFAIL (2/7)✗LynchFAIL (3/6)•PiotroskiNEUTRAL (F-Score 5)✗DremanFAIL (3/10)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)•AckmanNEUTRAL (6/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1490/2370 (Top 62.9%))✗NeffFAIL (2/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
  • Profitability7% pass✓ 6✗ 26▾

    14 of 15 flag TRUP's profitability — Graham, Buffett, Lynch +11 more

    Positive EPS (10 years)1/15 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)1/15 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-7.6%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)1.0% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$21.1M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)P/E 76.6x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE6.7%
    ✗Lynch> 15%
    Net Income / Total Assets2.12%
    ✓PiotroskiROA > 0
    ROA Change YoY-1.19% -> 2.12% (delta: +3.32%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=9.78%, ROA=2.12%
    ✓PiotroskiCFO/Assets > ROA
    Pre-Tax Income / Revenue1.9%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity6.7%
    ✗Dreman> 12%
    Margin of SafetyP/E=76.6x, P/B=3.9x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-4.2% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency1/14 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue1.8%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity6.7%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-3.7% (2023) -> 1.0% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 11.8% -> 16.1%, operating margin -3.7% -> 1.0%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+1.78%; #2792/6340 (top 44.0%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+25.25%; #1704/3702 (top 46.0%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity+6.67%; #2264/5226 (top 43.3%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0345; #2091/5884 (top 35.5%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation8% pass✓ 2✗ 24▾

    11 of 12 flag TRUP's valuation — Graham, Lynch, Dreman +8 more

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio3.9x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)P/E 76.6x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    Price / EPS76.6x
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)16.7x
    ✗Dreman< 8x
    Price / Book Value per Share3.9x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=76.6x, OE Yield=1.4%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=76.6x, FCF Yield=5.1%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=76.6x, P/B=3.9x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share19.9x
    ✓Ackman<= 25
    Price vs. Trailing Low148% of trailing low ($23.27)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+1.78%; #2792/6340 (top 44.0%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.2676; #3851/6449 (top 59.7%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS76.6x
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share4.67x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+2.7%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+1.0454; #1727/5247 (top 32.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+5.81%; #1407/4519 (top 31.1%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+40.51%; #803/6202 (top 12.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth13% pass✓ 4✗ 8▾

    7 of 8 flag TRUP's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)P/E 76.6x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    EPS Growth Direction$-9.76 (2012) -> $0.45 (2025)
    ✓DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency1/14 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth16.0%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 11.8% -> 16.1%, operating margin -3.7% -> 1.0%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR23.4%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Valuation models40% pass✓ 2✗ 3▾

    Models split on TRUP at $34.48 — fair values range $5.76–$62.20

    Graham fair value$9.46
    ✗Graham-264.3% margin vs $34.48
    Buffett fair value$5.76
    ✗Buffett-498.6% margin vs $34.48
    Munger fair value$41.42
    ✓Munger+16.8% margin vs $34.48
    Pabrai fair value$7.77
    ✗Pabrai-343.8% margin vs $34.48
    Ackman fair value$62.20
    ✓Ackman+44.6% margin vs $34.48
  • Cash Flow50% pass✓ 7✗ 5▾

    5 of 10 pass — Dreman, Pabrai, Marks +2 more object

    Free Cash Flow Proxy$21.1M
    ✓BuffettPositive and growing
    FCF Positive and Growing$86.7M
    ✓LynchPositive and growing
    Operating Cash Flow$89.5M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=9.78%, ROA=2.12%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)16.7x
    ✗Dreman< 8x
    P/E or FCF YieldP/E=76.6x, FCF Yield=5.1%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive7/14 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap5.8%
    ✓Ackman>= 4%
    Price / FCF per Share19.9x
    ✓Ackman<= 25
    Positive Operating Cash Flow frequency9/14 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$86.7M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+5.81%; #1407/4519 (top 31.1%)
    ✗OshaughnessyTop 10% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Insurance
SIC Sector: Insurance Carriers
Size: Small Cap($1.5B)
Revenue: $1.4B+11.9% YoY
Net Income: $19.4M+301.7% YoY

Financial Snapshot

Operating Margin1.0%
Return on Equity5.1%
Debt / Equity0.27
Current Ratio1.69
EPS (Diluted)$0.45
Shares Retired−2.2% / −3.7% 2y

Similar Companies

UNHUNITEDHEALTH GROUP INC
$365.1B
PGRPROGRESSIVE CORP/OH/
$136.6B
MRSHMARSH & MCLENNAN COMPANIES, INC.
$98.8B
CILJFCHINA LIFE INSURANCE CO LTD
$85.1B
Sector-adjusted criteria: Insurer

Insurers file unclassified balance sheets with no inventory or current accounts, so those criteria are omitted rather than failed for missing data. Return-on-invested-capital tests are omitted too: float funds the balance sheet but never appears in invested capital, and the portfolio it is invested in would be subtracted as spare cash. Debt tests are kept — an insurer’s borrowings are real leverage on top of underwriting.

Shareholder Return

Fiscal 2025

Issued 2.2% of shares last year, 3.7% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-13
FY 2024
Sources
  • 10-K · 2025-02-27
FY 2023
Sources
  • 10-K · 2024-02-27
FY 2022
Sources
  • 10-K · 2023-02-16
FY 2021
Sources
  • 10-K · 2022-02-17
Market Cap$1.5Bcurrent------$1.4Best.$2.0Best.$1.1Best.$2.4Best.$3.9Best.
Revenue$1.6B↑11%$405.6M↑11%$392.9M↑11%$384.0M↑12%$1.4B↑12%$1.3B↑16%$1.1B↑22%$905.2M↑29%$699.0M
Operating Income$27.8M↑295%$9.5M↑63%$6.4M↑176%$4.8M↑424%$13.8M↑245%-$9.5M↑77%-$40.7M↑5%-$43.0M↓22%-$35.2M
Net Income$26.6M↑72%$9.3M↑58%$6.8M↓27%$4.9M↑429%$19.4M↑302%-$9.6M↑78%-$44.7M-$44.7M↓26%-$35.5M
EPS (Diluted)--$0.21↑62%$0.16↓27%$0.11↑467%$0.45↑296%$-0.23↑79%$-1.08↑2%$-1.10↓24%$-0.89
Gross Margin————16.1%↑15%13.9%↑18%11.8%↓12%13.5%↓10%14.9%
Operating Margin1.8%↑254%2.4%↑47%1.6%↑148%1.2%↑389%1.0%↑230%-0.7%↑80%-3.7%↑23%-4.8%↑6%-5.0%
ROE6.7%↑59%———5.1%↑270%-3.0%↑80%-14.7%↓1%-14.6%↓37%-10.7%
Total Debt$104.5M↓9%$104.5M↓9%$106.9M↓7%$109.3M↓15%$101.8M↓20%$127.5M$127.6M↑87%$68.4M$0
Shareholders' Equity$399.2M↑8%$399.2M↑8%$409.7M↑15%$394.8M↑18%$383.9M↑19%$323.3M↑6%$303.7M↓1%$305.3M↓8%$332.2M
Current Ratio1.74↑2%1.74↑2%1.77↑5%1.73↑2%1.69↓1%1.71↑5%1.63↑1%1.62↓7%1.75
Debt / Equity0.26↓16%0.26↓16%0.26↓19%0.28↓28%0.27↓33%0.39↓6%0.42↑88%0.220.00
Operating Cash Flow$95.6M↑14%$30.7M↑5%$21.0M↑40%$14.6M↓9%$89.5M↑85%$48.3M↑159%$18.6M↑333%-$8.0M↓207%$7.5M
Free Cash Flow$86.7M↑21%$28.5M↑19%$19.2M↑59%$13.7M↓2%$75.4M↑95%$38.6M↑10674%$358.0K↑101%-$25.1M↓412%-$4.9M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Insurance

TRUP vs Peers — Financial Grading

Revenue$1.4BBottom 25%
Net Income$19.4MBottom 25%
ROE5.1%Bottom 25%
D/E0.27Median
Op. Margin1.0%Bottom 25%
Curr. Ratio1.69Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchPiotroskiDreman
UNITEDHEALTH GROUP INCUNH$365.1B$407.46$447.6B$12.1B12.0%0.784.2%0.793/74/72/6F-Score 63/10
PROGRESSIVE CORP/OH/PGR$136.6B$235.78$87.7B$11.3B37.3%0.23——2/72/74/6F-Score 68/10
MARSH & MCLENNAN COMPANIES, INC.MRSH$98.8B$207.78$27.0B$4.2B27.2%1.2823.1%1.103/73/72/6F-Score 65/10
CHINA LIFE INSURANCE CO LTDCILJF$85.1B$3.01——————5/71/73/6F-Score 55/10
Aon plcAON$71.8B$338.31$17.2B$3.7B39.5%1.6325.3%1.112/74/73/6F-Score 63/10
HUMANA INCHUM$54.0B$450.00$129.7B$1.2B6.7%0.702.1%2.003/72/71/6F-Score 44/10
SUN LIFE FINANCIAL INCSLF$40.5B$72.93$30.6B$2.6B14.5%0.33——3/73/72/6F-Score 66/10
HARTFORD INSURANCE GROUP, INC.HIG$36.8B$137.48$28.4B$3.8B20.2%0.23——3/73/74/6F-Score 78/10